Emil Pop Pages 1347 - 1359 ( 13 )
Unlike natural cannabinoids which belong to the 6aR - trans series, the synthetic dexanabinol (HU-211), a 6aS-trans enantiomer, does not have affinity toward cannabinoid receptors and is devoid of cannabimimetic activity. On the other hand, dexanabinol demonstrated significant neuroprotective properties which prompted its development as a therapeutic agent. We now present the extension of a series of 6aS-trans cannabinoids with novel derivatives, including water soluble derivatives and congeners of dexanabinol.
Nonpsychotropic Synthetic Cannabinoids,6aR - trans series,synthetic dexanabinol (HU-211),a 6aS-trans enantiomer,cannabimimetic activity,neuroprotective properties,therapeutic agent,6aS-trans cannabinoids,Delta 9 tetrahydrocannabinol (THC),6aS-trans enantiomeric series,noncompetitive N-methyl-D-aspartate (NMDA),tumor necrosis factor (TNF alpha),NMDA,Structures of dexanabinol (1) and HU-210 (2),DEXANABINOL,PM3,Glycinate,substituted glycinate esters,Hetrocyclic nitrogen containing esters,Phenolic ester,Phosphate esters,Hemiesters,Pyridine 3 carboxylates,NMDA Receptor Binding,6aS trans cannabinoids,Lactate dehydrogenase (LDH),NMDA Receptor binding properties,Novel 6aS trans cannabinoids,Gas or liquid chromatographic mass spectrometry (GC MS or LC-MS)
Alchem Laboratories Corporation, 13305 Rachael Boulevard, Alachua, FL, USA